ATG changes name to Avitech Diagnostics:
This article was originally published in Clinica
Executive Summary
US company Applied Technology Genetics has changed its name to Avitech Diagnostics, reflecting the company's emphasis on developing new diagnostic procedures for the detection of cancer and cardiovascular diseases. Avitech's lead technology, Enzymatic Mismatch Scanning (EMS), uses specialised DNA repair and replication enzymes for the in vitro detection of mutated DNA sequences. EMS has proved to be effective in the detection of several genes that occur in human cancers, including p53 and BRCA1.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.